How will the implementation of NAT for HBV affect the residual risk estimates for transfusion-transmitted HBV?
The following table shows the change in infectious window period, the percentage of window period closure and the residual risk estimates for HBV following the implementation of HBV NAT. The window period closure of 37.6% for HBV will reduce the residual risk of transfusion transmitted HBV from 1 in 739,000 to less than 1 in 1 million.
Related Questions
- How will the introduction of HBV NAT reduce the residual risk of transfusion-transmitted HBV infection?
- How does the Australian residual risk estimate for transfusion-transmitted HBV compare internationally?
- How will the Microsoft Kerberos implementation affect my access to non-Microsoft Kerberos services?
